2. Gene
  3. CDK2 - cyclin dependent kinase 2 Gene

CDK2 - cyclin dependent kinase 2 Gene

  • 基因
  • 蛋白
  • 相关产品
  • 直系同源

中文名称：细胞周期蛋白依赖性激酶 2

种属: Canis lupus familiaris (sub-species: familiaris)

基因 ID: 100855704 | 基因类型: protein coding

关于 CDK2

Primary_assembly 10: 307,694-312,540 forward strand.ROS_Cfam_1.0:CM025109.1

This gene has 4 transcripts (splice variants), 203 orthologues and 25 paralogues.

CDK2 基因产物(4)

mRNA Protein Name
XM_038678951.1 XP_038534879.1 cyclin-dependent kinase 2 isoform X2
XM_038678952.1 XP_038534880.1 cyclin-dependent kinase 2 isoform X3
XM_038678950.1 XP_038534878.1 cyclin-dependent kinase 2 isoform X1
XM_038678953.1 XP_038534881.1 cyclin-dependent kinase 2 isoform X4

CDK2 蛋白结构

STKc_CDK2_3

STKc_CDK2_3: cd07860 (2 - 333)

  • 0
  • 100
  • 200
  • 300
  • 346 a.a.
蛋白主名 其他名称

cyclin-dependent kinase 2

相关产品

Approval
生物活性分子 (6)
目录号 产品名 作用方式
纯度 是否罕见病
HY-16297A Abemaciclib Inhibitor 99.96% 是
HY-10492 Dinaciclib Inhibitor 99.44% 是
HY-16297 Abemaciclib methanesulfonate Inhibitor 99.95% 是
HY-B0402 Amantadine Inhibitor ≥98.0% 是
HY-B0402A Amantadine hydrochloride Inhibitor ≥98.0% 是
HY-B0402B Amantadine sulfate Inhibitor / 否
Clinical Phase
生物活性分子 (25)
目录号 产品名 作用方式
纯度 Phase
HY-10580 GSK 3 Inhibitor IX Inhibitor 99.74% Phase 4
HY-10005 Flavopiridol Inhibitor 99.72% Phase 2
HY-30237 (R)-Roscovitine Inhibitor 98.73% Phase 2
HY-101212 Fadraciclib Inhibitor 99.78% Phase 2
HY-50940 AT7519 Inhibitor 99.76% Phase 2
HY-10006 Flavopiridol Hydrochloride Inhibitor 98.95% Phase 2
HY-103712A Samuraciclib hydrochloride Inhibitor 99.98% Phase 2
HY-13914 Roniciclib Inhibitor 98.03% Phase 2
HY-10424 Milciclib Inhibitor 99.89% Phase 2
HY-103712B Samuraciclib hydrochloride hydrate Inhibitor 99.08% Phase 2
HY-16559 Riviciclib hydrochloride 99.01% Phase 2
HY-50943 AT7519 Hydrochloride Inhibitor 99.42% Phase 2
HY-112272A Lerociclib dihydrochloride Inhibitor 99.74% Phase 2
HY-112272 Lerociclib Inhibitor / Phase 2
HY-16559A Riviciclib Inhibitor / Phase 2
HY-138293 SY-5609 Inhibitor 99.66% Phase 1
HY-10008 SNS-032 Inhibitor 99.49% Phase 1
HY-10012 AZD-5438 Inhibitor 99.85% Phase 1
HY-141680 CPS2 Inhibitor 99.33% Phase 1
HY-12871B Atuveciclib Inhibitor 99.80% Phase 1
HY-11001 PHA-793887 Inhibitor 99.25% Phase 1
HY-111361 FN-1501 Inhibitor 99.71% Phase 1
HY-15504 RGB-286638 Inhibitor 99.84% Phase 1
HY-15504A RGB-286638 free base Inhibitor 98.07% Phase 1
HY-50940A AT7519 TFA Inhibitor 98.53% Phase 1
Pre-clinical Phase
生物活性分子 (122)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-12529 Ro-3306 Inhibitor 99.04% 否
HY-12302 Kenpaullone Inhibitor 98.16% 否
HY-103248 Toyocamycin Inhibitor 99.90% 否
HY-10329 JNJ-7706621 Inhibitor 99.91% 否
HY-130665 TL12-186 Inhibitor ≥99.0% 否
HY-101257 YKL-5-124 Inhibitor 98.03% 否
HY-15166 (E/Z)-Zotiraciclib Inhibitor 99.96% 否
HY-124719 hSMG-1 inhibitor 11j Inhibitor 99.81% 否
HY-130709 PROTAC CDK2/9 Degrader-1 Inhibitor 99.85% 否
HY-15004 AUZ 454 Inhibitor 99.57% 否
HY-11009 CGP60474 Inhibitor 99.23% 否
HY-15339 CVT-313 Inhibitor 99.76% 否
HY-127104 FMF-04-159-2 Inhibitor 98.92% 否
HY-10014 R547 Inhibitor 99.57% 否
HY-15275 BMS-265246 Inhibitor 98.92% 否
HY-123772 CDK5 inhibitor 20-223 Inhibitor 99.78% 否
HY-13266A BS-181 hydrochloride Inhibitor 99.80% 否
HY-13461A PHA-767491 hydrochloride Inhibitor 98.06% 否
HY-18299A Purvalanol A Inhibitor 98.30% 否
HY-18299 Purvalanol B Inhibitor ≥97.0% 否
HY-15569 NU6102 Inhibitor 99.68% 否
HY-18340A (R)-CR8 trihydrochloride Inhibitor 98.95% 否
HY-18629 SU9516 Inhibitor 99.81% 否
HY-117535 CDK2-IN-4 Inhibitor 98.07% 否
HY-112626 CDK12-IN-2 Inhibitor 99.44% 否
HY-W011428 Olomoucine Inhibitor 99.78% 否
HY-12445 Asnuciclib Inhibitor 99.76% 否
HY-101257B YKL-5-124 TFA Inhibitor 99.44% 否
HY-117203A CDK12-IN-E9 Inhibitor 99.97% 否
HY-15878 LDC000067 Inhibitor 98.00% 否
HY-124760 hSMG-1 inhibitor 11e Inhibitor 99.18% 否
HY-18340 (R)​-​CR8 Inhibitor 99.21% 否
HY-X0150 JSH-150 Inhibitor 98.36% 否
HY-18930 NU6300 Inhibitor 96.34% 否
HY-144117 GFB-12811 Inhibitor 98.00% 否
HY-15889 AMG 925 Inhibitor 98.24% 否
HY-103647 K00546 Inhibitor 98.08% 否
HY-119940 MC180295 Inhibitor 98.41% 否
HY-108136A Bisindolylmaleimide X hydrochloride Antagonist 99.35% 否
HY-12280 THZ2 Inhibitor 99.03% 否
HY-107419 NU6140 Inhibitor 99.51% 否
HY-100600 BGG463 Inhibitor ≥98.0% 否
HY-15241 NVP-LCQ195 Inhibitor 98.91% 否
HY-103712C Samuraciclib hydrochloride hydrate Inhibitor 99.88% 否
HY-108359 Alsterpaullone Inhibitor 98.38% 否
HY-137443 Ipivivint Inhibitor 99.65% 否
HY-103646 CK7 Inhibitor 99.23% 否
HY-12843 Bohemine Inhibitor 98.93% 否
HY-148062 RSS0680 98.03% 否
HY-145694 CDK5-IN-3 Inhibitor 98.00% 否
HY-15166A (E/Z)-Zotiraciclib hydrochloride Inhibitor 99.45% 否
HY-41076 Ca2+ channel agonist 1 Inhibitor 99.71% 否
HY-100429 CAN508 Inhibitor 99.59% 否
HY-N5072 Desmethylglycitein Inhibitor 98.98% 否
HY-112468 PNU112455A hydrochloride Inhibitor 99.56% 否
HY-19316 NU2058 Inhibitor 98.78% 否
HY-153556 GW297361 Inhibitor 98.13% 否
HY-112460 CDK2-IN-3 Inhibitor ≥95.0% 否
HY-15166B (E/Z)-Zotiraciclib citrate Inhibitor 98.06% 否
HY-111207 CA224 Inhibitor 99.94% 否
HY-112358 GW8510 Inhibitor 99.64% 否
HY-15889A AMG 925 HCl Inhibitor / 否
HY-W019806 Lacto-N-fucopentaose I Activator ≥90.0% 否
HY-13816 NU6027 Inhibitor 99.35% 否
HY-139980 CDK9-IN-13 Inhibitor 99.22% 否
HY-13266 BS-181 Inhibitor 98.10% 否
HY-139011 IV-361 Inhibitor 98.64% 否
HY-148868 Akt1&PKA-IN-1 Inhibitor / 否
HY-154851 GSK-3 inhibitor 3 Inhibitor 98.72% 否
HY-142076 CDK4/6-IN-15 Inhibitor / 否
HY-144117A (S)-GFB-12811 Inhibitor 97.12% 否
HY-148868A Akt1&PKA-IN-2 Inhibitor / 否
HY-114903 (E/Z)-BIO-acetoxime Inhibitor / 否
HY-139328 CDK12-IN-5 Inhibitor 99.01% 否
HY-14372 BS-194 Inhibitor 99.36% 否
HY-13461 PHA-767491 Inhibitor / 否
HY-151409 CDK1-IN-5 Inhibitor / 否
HY-151436 ZLMT-12 Inhibitor / 否
HY-151407 CDK1-IN-3 Inhibitor / 否
HY-143497 HDAC1/2 and CDK2-IN-1 Inhibitor / 否
HY-130001 CDK9-IN-9 Inhibitor / 否
HY-110368 BS-181 dihydrochloride Inhibitor / 否
HY-130981 FN-1501-propionic acid / 否
HY-103712 Samuraciclib Inhibitor / 否
HY-148214 CDK2/4/6-IN-2 Inhibitor / 否
HY-147698 ZLHQ-5f Inhibitor / 否
HY-151408 CDK1-IN-4 Inhibitor / 否
HY-115943 Anticancer agent 30 Inhibitor / 否
HY-155787 SHR5428 Inhibitor / 否
HY-145693 CDK5-IN-2 Inhibitor / 否
HY-146276 CDK/HDAC-IN-2 Inhibitor / 否
HY-151878 CDK7-IN-20 Inhibitor / 否
HY-139651 CDK2-IN-7 Inhibitor / 否
HY-151580S CDK2-IN-14-d3 Inhibitor / 否
HY-139329 CDK12-IN-6 Inhibitor / 否
HY-112346 RGB-286147 Inhibitor / 否
HY-155441 CDK2-IN-20 Inhibitor / 否
HY-147409 Ulecaciclib Inhibitor / 否
HY-142696 CDK6/PIM1-IN-1 Inhibitor / 否
HY-150573 CDK2-IN-12 Inhibitor / 否
HY-150641 CDK-IN-9 Inhibitor / 否
HY-151984 CDK9-IN-22 Inhibitor / 否
HY-136726 CGP-82996 Inhibitor / 否
HY-146253 CDK1/2/4-IN-1 Inhibitor / 否
HY-149407 Multi-kinase-IN-4 Inhibitor / 否
HY-154852 GSK-3 inhibitor 4 Inhibitor / 否
HY-141685 3-Methylthienyl-carbonyl-JNJ-7706621 Inhibitor / 否
HY-112363 Aloisine A Inhibitor / 否
HY-147771 ZLWT-37 Inhibitor / 否
HY-144810 CDK2-IN-8 Inhibitor / 否
HY-150570 Carbonic anhydrase inhibitor 14 Inhibitor / 否
HY-145867 EGFR-IN-45 Inhibitor / 否
HY-148213 CDK2/4/6-IN-1 Inhibitor / 否
HY-148651 CDK2-IN-15 Inhibitor / 否
HY-115942 Anticancer agent 29 Inhibitor / 否
HY-144811 CDK2-IN-9 Inhibitor / 否
HY-100035 PT-262 Inhibitor 99.21% 否
HY-139327 CDK12-IN-4 Inhibitor / 否
HY-151898 CDK4/6-IN-14 Inhibitor / 否
HY-156470 Multi-kinase-IN-6 Inhibitor / 否
HY-111356 IIIM-290 Inhibitor / 否
HY-111932 Indirubin-5-sulfonate Inhibitor / 否

直系同源

种属 基因名 来源 基因 ID
Homo sapiens CDK2 NCBI NCBI:1017